Clinical Trial

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-02-09.
Status change: Not Yet Recruiting → Recruiting 2025-11-16
Trial Details
NCT Number NCT05236686
Lead Sponsor Shanghai Gynecologic Oncology Group
Collaborators: Fudan University
Conditions Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Enrollment 94 participants
Start Date 2022-02-15
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-19